Price movement over the last 24 hours
ADMA Biologics Inc vs Sprott Uranium Miners ETF — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Sprott Uranium Miners ETF trades at $51.02. Which is the better fit depends on your goals.
| ADMA | URNM | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $83.99 |
52-Week Low | $7.60 | $44.14 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
URNM trades at $53.56, up 1.38% today, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned at the intersection of AI-driven electricity demand and nuclear energy growth, with recent news highlighting uranium's role in powering data centers. Key support lies at $52, while resistance is near $54.
Outlook is mixed: long-term growth is supported by nuclear energy demand, but short-term risks include volatility in uranium prices and miner equity valuations. Investment opportunity hinges on the AI power narrative, yet caution is warranted due to technical weakness and concentrated miner exposure.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →